Twist Bioscience (TWST) investors back board slate and Ernst & Young at 2026 meeting

Rhea-AI Filing Summary

Twist Bioscience Corporation held its 2026 Annual Meeting of Stockholders, with strong participation from holders of 56,260,506 common shares, representing about 91.81% of shares eligible to vote. This high turnout indicates that most stockholders were represented, either in person or by proxy.

Stockholders elected three Class II directors to three-year terms: Keith Crandell, Jan Johannessen, and Trynka Shineman Blake. Blake received 50,217,493 votes for and 88,210 votes withheld, while Crandell and Johannessen each also secured substantial majorities, ensuring continuity on the board.

Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 38,430,673 votes for, 11,842,367 against, and 32,663 abstentions, along with 5,954,803 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with 56,220,551 votes for, 18,170 against, and 21,785 abstentions.

FALSE000158128000015812802024-11-182024-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 5, 2026

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-38720

46-2058888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I. R. S. Employer Identification No.)

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

TWST

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2026 Annual Meeting of Stockholders of Twist Bioscience Corporation (the "Company"), there were present, in person or by proxy, holders of 56,260,506 shares of common stock, or approximately 91.81% of the total outstanding shares eligible to be voted. The holders present voted on the three proposals presented at the Annual Meeting as follows.

Proposal One — Election of Directors

The Company’s stockholders approved the election of three directors to the Company’s Board of Directors as Class II Directors to serve for the ensuing three years and until their successors are elected and qualified or until their earlier resignation or removal, by the following votes:

Nominee						Votes For						Votes Withheld						Broker Non-Votes
Keith Crandell						40,500,506						9,805,197						5,954,803
Jan Johannessen						42,319,597						7,986,106						5,954,803
Trynka Shineman Blake						50,217,493						88,210						5,954,803

Proposal Two — Non-Binding, Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers (“NEOs”)

The Company’s stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of the Company’s NEOs, by the following votes:

Votes For						Votes Against						Abstentions						Broker Non-Votes
38,430,673						11,842,367						32,663						5,954,803

Proposal Three — Ratification of Appointment of Independent Registered Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered accounting firm for the fiscal year ending September 30, 2026, by the following votes:

Votes For						Votes Against						Abstentions
56,220,551						18,170						21,785

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 6, 2026			Twist Bioscience Corporation
			/s/ Judy Yan
			Judy Yan
			Assistant General Counsel and Assistant Secretary

FAQ

What was the shareholder turnout at Twist Bioscience (TWST) 2026 annual meeting?

Twist Bioscience reported that holders of 56,260,506 common shares were present in person or by proxy, representing approximately 91.81% of outstanding shares eligible to vote. This indicates a very high level of shareholder participation in the 2026 annual meeting.

Which directors were elected at Twist Bioscience (TWST) 2026 annual meeting?

Stockholders elected three Class II directors: Keith Crandell, Jan Johannessen, and Trynka Shineman Blake, each to serve for three years. Blake received 50,217,493 votes for, with only 88,210 votes withheld, reflecting strong support for the board slate overall.

How did Twist Bioscience (TWST) shareholders vote on executive compensation in 2026?

Shareholders approved the non-binding advisory resolution on compensation of named executive officers, with 38,430,673 votes for, 11,842,367 against, and 32,663 abstentions. There were also 5,954,803 broker non-votes, but the proposal passed with a clear majority in favor.

Which audit firm did Twist Bioscience (TWST) shareholders ratify for fiscal 2026?

Stockholders ratified Ernst & Young LLP as Twist Bioscience’s independent registered accounting firm for the fiscal year ending September 30, 2026. The vote was strongly supportive, with 56,220,551 votes for, 18,170 against, and 21,785 abstentions recorded in the final tally.

Were there any broker non-votes reported at Twist Bioscience (TWST) 2026 meeting?

Yes. For the director elections and the advisory vote on executive compensation, there were 5,954,803 broker non-votes. Broker non-votes occur when brokers lack authority to vote uninstructed shares on certain proposals, but the affected proposals still passed.

How close were the voting results for Twist Bioscience (TWST) auditor ratification?

The ratification of Ernst & Young LLP passed by a very wide margin, with 56,220,551 votes for, 18,170 against, and 21,785 abstentions. The low number of votes against suggests broad shareholder support for continuing with the same audit firm.